Similar short-and long-term colectomy rates with ciclosporin and infliximab treatment in hospitalised ulcerative colitis patients

Journal of Crohn's and Colitis

Volumn 10, Issue 7, 2016, Pages 821-827

  Duijvis, Nicolette W ^a   ten Hove, Anne S ^a   Ponsioen, Cyriel I J ^a   van den Brink, Gijs R ^a   Buskens, Christianne J ^a   Bemelman, Willem A ^a   te Velde, Anje A ^a   D'Haens, Geert R A M ^a   Löwenberg, Mark ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Colectomy; Remission induction treatment; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; CYCLOSPORIN;

ADULT; ARTICLE; CLINICAL OUTCOME; COLON RESECTION; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COLITIS, ULCERATIVE; HOSPITALIZATION; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; COLECTOMY; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85012207609     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw031     Document Type: Article

References (21)

1. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-7.
2. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
3. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
5. Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut 2011;60:130-3.
6. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-15.
7. Seagrove AC, Alam MF, Alrubaiy L, et al. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). BMJ Open 2014;4:e005091.
8. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013;38:294-302.
9. Naves JE, Llao J, Ruiz-Cerulla A, et al. Long-term comparative efficacy of cyclosporine-or infliximab-based strategies for the management of steroidrefractory ulcerative colitis attacks. Inflamm Bowel Dis 2014;20:1375-81.
10. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011;106:771-7.
11. de Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol 2004;4:9.
12. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73-8.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
14. Christophorou D, Funakoshi N, Duny Y, et al. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12.
15. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400 e3.
16. Lowenberg M, Duijvis NW, Ponsioen C, van den Brink GR, Fockens P, D'Haens GR. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis. Eur J Gastroenterol Hepatol 2014;26:1240-6.
17. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008;12:1738-44.
18. Halfvarson J, Jarnerot G. Treatment of choice for acute severe steroid-refractory ulcerative colitis is remicade. Inflamm Bowel Dis 2009;15:143-5.
19. Reich KM, Chang HJ, Rezaie A, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther 2014;40:629-38.
20. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015;149:350-5 e2.
21. Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:330-5 e1.